Researchers still don’t know how well BA.2.86 will evade immunity or whether it will cause more severe disease than its predecessors.
Articles on Delta variant
Displaying 1 - 20 of 100 articles
With the emergency phase of the COVID-19 pandemic in the rearview mirror, at least for now, we look back on a handful of stories that provided sharp insights at key moments in the pandemic.
It’s hard to keep up. But new Omicron sub-variants are emerging that may lead to reinfections and another spike in cases.
New data on the second booster suggests the older you are, the more you need it.
More than 1,000 cases of omicron XE have been detected in the UK so far. But we shouldn’t be seriously concerned at this stage.
Vaccine passports became one of the most divisive issues of the COVID-19 pandemic. These policies were affected not only by public opinion but by new variants and changing goals for herd immunity.
Hybrid viruses that are part delta and part omicron have been found in Europe and North America.
Improving genomic surveillance to better understand new variants as they arise in different parts of the world could prevent threats to vulnerable health systems and populations.
The CDC’s controversial recommendation changes are based on new studies showing that most omicron transmission takes place within five days of the onset of illness.
Three months after Omicron abruptly arrived, we now know more about the variant. So what does the science say about how contagious it is, how long it takes to get sick and how effective vaccines are?
A growing body of research shows that COVID-19 protocols should be extended to areas in which there is a human-animal interface such as zoos, wildlife sanctuaries and game farms.
Some of the omicron variant’s unique properties – such as its ability to spread rapidly while causing milder COVID-19 infections – could usher in a new phase of the pandemic.
Variant-specific vaccines would undoubtedly increase immunity. But waves of new variants would engulf the population faster than these vaccines could ever be deployed.
People are buzzing with questions about the omicron variant and whether it could help usher in herd immunity. A team of virologists deciphers the latest findings.
A nationwide genomic surveillance system analyzes positive COVID-19 tests to build a picture of which variants are spreading in the population.
The prime minister’s inflexibility on the home-testing COVID tests is beyond curious - especially in an election year.
One of the ways the Omicron variant is different from other variants is the sheer number of mutations in the spike protein. Does this make it a super-variant?
At this stage, we cannot say anything about the severity of cases with Omicron - either in primary or reinfections.
Careful lab work will complement public health data as researchers worldwide focus on omicron, asking questions about contagiousness, severity of disease and whether vaccines hold up against it.
Evidence suggests kids under 12 aren’t major drivers of COVID spread. Avoiding them isn’t necessary.
Top contributors
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor in Applied Mathematics, University of Canterbury
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Epidemiology, Medicine, and Infectious Diseases and Microbiology, University of Pittsburgh
-
Adjunct Professor of Epidemiology, University of Texas Health Science Center at Houston
-
Professor and Tier 1 Canada Research Chair in Global Health Governance; Scientific Co-Director, Bridge Research Consortium, Simon Fraser University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Paediatrician and Infectious Diseases Specialist; Clinical Researcher, University of Sydney
-
Professor and Department Chair of Infectious Diseases and Microbiology, University of Pittsburgh
-
Professor of Epidemiology, University of Auckland, Waipapa Taumata Rau
-
Research Fellow, Pandemics & Borders Project, Simon Fraser University
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
Associate Professor and Research Leader in Virology and Infectious Disease, Griffith University
-
Associate Professor, Child and Adolescent Health, University of Sydney
-
Head: Zoonotic, Arbo and Respiratory Virus Programme, Professor, Department Medical Virology, University of Pretoria